Baxter Surges 11% After Q2 Smash, Lifts 2026 Outlook on Turnaround Momentum
BAX sits 70% above its 52-week low of $15.73 on elevated volume (1.8× avg).
Summary
Baxter delivered a clean Q2 beat with adjusted EPS of $0.54 vs. $0.37 consensus and revenue of $2.96B vs. $2.795B, driven by strength in advanced surgery and drug compounding. The company raised full-year 2026 adjusted EPS guidance to $1.95-$2.15 (from $1.85-$2.05) and sales guidance to $11.58B-$11.69B, both above consensus. Shares jumped 11% to $27.49, reflecting conviction in the turnaround narrative. CEO Hider noted improved execution but cautioned that the turnaround is still early. The Medical Products & Therapies segment led with 7% reported growth, while Healthcare Systems & Technologies grew 4%. This follows the segment realignment announced two weeks ago and the Q1 net loss, making the beat and raise a material positive signal. Watch for sustained margin expansion in H2 as higher-cost inventory rolls off.
At the time of this announcement, BAX was trading at $26.71 on NYSE in the Life Sciences sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $15.73 to $30.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.